Show simple item record

dc.contributor.authorHervás Aguilar, América
dc.contributor.authorPuebla Jiménez, Lilian 
dc.contributor.authorBurgos Ramos, Emma 
dc.contributor.authorAguado Llera, David 
dc.contributor.authorArilla Ferreiro, Eduardo
dc.identifier.bibliographicCitationNeuroscience, 2005, v. 135, n. 1, p. 181–190en
dc.description.abstractIt is unknown whether the amyloid β-peptide (Aβ), a principal component found in extracellular neuritic plaques in the brain of patients with Alzheimer’s disease (AD), is capable of altering adenylyl cyclase (AC) activity and the somatostatin (SRIF) receptor-effector system in the cerebral cortex of the patients. Therefore, the objective of this study was to investigate the effect of the β fragment, β (25–35), on AC activity and the somatostatinergic system in the rat frontoparietal cortex. A single dose of β (25–35) (10μg) injected intracerebroventricularly significantly decreased the density of SRIF receptors (27.4%) and increased their affinity (32.2%) in the frontoparietal cortex. The inhibitory effect of SRIF on basal and forskolin (FK)-stimulated AC activity was significantly lower in the β (25–35)-treated rats when compared with controls. β (25–35) did not modify Giα1, Giα2 nor Giα3 levels in membranes from the frontoparietal cortex. Continuous infusion of the peptide induced a decrease in the SRIF receptor density in this brain area to a similar extent as that observed 14 days after the single administration of the peptide. Likewise, this treatment decreased the SRIF receptor density in the frontal cortex (15.3%) and parietal cortex (27.2%). This effect was accompanied by a decrease in the SRIF-mediated inhibition of FK-stimulated AC activity (from 41.6% to 25.6%) in the frontal cortex as well by a decrease in basal AC activity (from 36.9% to 31.6%) and FK-stimulated AC activity (from 35.6% to 27.1%) in the parietal cortex. Continuous infusion of Aβ (25–35) had no effect on Giα1, Giα2 or Giα3 levels in membranes from frontal and parietal cortex. However, this treatment caused a decrease in SRIF-like immunoreactivity content in the parietal (38.9%) and frontal (20.4%) cortex. These results suggest that Aβ might be involved in the alterations of somatostatinergic system reported in AD.en
dc.publisherNature Publishing Groupen
dc.rights© Elsevier, 2005en
dc.subjectAlzheimer's diseaseen
dc.subjectSomatostatin receptorsen
dc.subjectCerebral cortexen
dc.titleEffects of single and continuous administration of amyloid ß-peptide (25-35) on adenylyl cyclase activity and the somatostatinergic system in the rat frontal and parietal cortexen
dc.contributor.affiliationUniversidad de Alcalá. Departamento de Bioquímica y Biología Molecular
dc.relation.projectIDPM99-0129 (Ministerio de Ciencia y Tecnología)

Files in this item


This item appears in the following Collection(s)